NGNE vs. NRIX, OCUL, ARVN, DAWN, ARDX, CALT, GYRE, SYRE, NTLA, and ANIP
Should you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include Nurix Therapeutics (NRIX), Ocular Therapeutix (OCUL), Arvinas (ARVN), Day One Biopharmaceuticals (DAWN), Ardelyx (ARDX), Calliditas Therapeutics AB (publ) (CALT), Gyre Therapeutics (GYRE), Spyre Therapeutics (SYRE), Intellia Therapeutics (NTLA), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry.
Neurogene vs.
Neurogene (NASDAQ:NGNE) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, media sentiment, institutional ownership, earnings, profitability, valuation and risk.
Nurix Therapeutics received 49 more outperform votes than Neurogene when rated by MarketBeat users. However, 100.00% of users gave Neurogene an outperform vote while only 78.95% of users gave Nurix Therapeutics an outperform vote.
Neurogene has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500.
Neurogene has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -313.65%. Neurogene's return on equity of -32.81% beat Nurix Therapeutics' return on equity.
Neurogene currently has a consensus target price of $60.83, indicating a potential upside of 163.12%. Nurix Therapeutics has a consensus target price of $30.35, indicating a potential upside of 57.92%. Given Neurogene's stronger consensus rating and higher possible upside, equities research analysts clearly believe Neurogene is more favorable than Nurix Therapeutics.
Neurogene has higher earnings, but lower revenue than Nurix Therapeutics.
52.4% of Neurogene shares are held by institutional investors. 9.9% of Neurogene shares are held by company insiders. Comparatively, 7.2% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Neurogene and Neurogene both had 3 articles in the media. Neurogene's average media sentiment score of 0.22 beat Nurix Therapeutics' score of 0.16 indicating that Neurogene is being referred to more favorably in the media.
Summary
Neurogene beats Nurix Therapeutics on 12 of the 16 factors compared between the two stocks.
Get Neurogene News Delivered to You Automatically
Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neurogene Competitors List
Related Companies and Tools
This page (NASDAQ:NGNE) was last updated on 1/6/2025 by MarketBeat.com Staff
